Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis

Arthritis Rheum. 2004 Oct 15;51(5):691-9. doi: 10.1002/art.20696.


Objective: To assess the usefulness of measuring serum matrix metalloproteinase 3 (MMP-3) and macrophage colony-stimulating factor (M-CSF) in patients with ankylosing spondylitis (AS).

Methods: Serum levels of MMP-3 and M-CSF were measured in AS patients who did and did not receive infliximab treatment. These were compared with those of 28 healthy subjects.

Results: In the group of AS patients not treated with biologics, both M-CSF and MMP-3 correlated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) values, but not with each other. Logistic regression analysis showed that MMP-3 values were high in those with severely active disease. Infusions of infliximab in AS patients led to a significant decrease in the values of the BASDAI as well as the serum MMP-3, but no change in the serum M-CSF values.

Conclusion: MMP-3 and M-CSF are potentially useful markers of AS disease activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Biomarkers
  • Female
  • Humans
  • Infliximab
  • Macrophage Colony-Stimulating Factor / blood*
  • Macrophage Colony-Stimulating Factor / genetics
  • Male
  • Matrix Metalloproteinase 3 / blood*
  • Matrix Metalloproteinase 3 / genetics
  • Middle Aged
  • Oligonucleotide Array Sequence Analysis
  • Severity of Illness Index
  • Spondylitis, Ankylosing / blood*
  • Spondylitis, Ankylosing / drug therapy
  • Spondylitis, Ankylosing / genetics


  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Biomarkers
  • Macrophage Colony-Stimulating Factor
  • Infliximab
  • Matrix Metalloproteinase 3